FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:747-750 March 7, 2002 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective by Swartz, M. N. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The emergence of Streptococcus pneumoniae that is resistant to the -lactam and macrolide antimicrobial drugs has aroused concern about the use of these agents for the empirical treatment of community-acquired pneumonia.¹ Fluoroquinolones with increased activity against S. pneumoniae, such as levofloxacin, moxifloxacin, and gatifloxacin, are now being recommended for the treatment of patients with community-acquired pneumonia whose infection is likely to have been caused by multidrug-resistant strains.^1,2,3,4,5,6 However, there has been relatively little experience with the use of these agents, as compared with the -lactam and macrolide antimicrobial agents, as monotherapy for community-acquired pneumonia.

We describe four patients with pneumococcal . . . [Full Text of this Article]

Case Reports

Patient 1

Patient 2

Patient 3

Patient 4

Methods

Results

Discussion

Source Information

From Queen Elizabeth Health Sciences Centre, Halifax, N.S. (R.D.); University Health Network, Toronto (R.C., J.L.B., D.E.L.); Toronto Medical Laboratories and the Department of Microbiology, Mount Sinai Hospital, Toronto (J.L.B., D.J.B., J.C.S.A., D.E.L.); the University of Toronto, Toronto (R.C., J.L.B., D.J.B., J.C.S.A., D.E.L.); Victoria General Hospital, Victoria, B.C. (P.K.); and the Quality Management Program–Laboratory Services, Ontario Medical Association, Toronto (C.F., D.E.L.) — all in Canada.

Address reprint requests to Dr. Low at the Department of Microbiology, Mount Sinai Hospital, 600 University Ave., Rm. 1487, Toronto, ON M5G 1X5, Canada, or at dlow@mtsinai.on.ca.

References

Related Letters:

Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Ross J. J., Worthington M. G., Gorbach S. L., Tillotson G. S., Zhao X., Drlica K., Zhanel G. G., Hoban D. J., Chan C. K., Hutchinson J., Low D. E., de Azavedo J., Bast D.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:65-67, Jul 4, 2002. Correspondence

This article has been cited by other articles:

• Yamamoto, K., Yanagihara, K., Sugahara, K., Imamura, Y., Seki, M., Izumikawa, K., Kakeya, H., Yamamoto, Y., Hirakata, Y., Kamihira, S., Kohno, S. (2009). In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms. Antimicrob. Agents Chemother. 53: 3572-3575 [Abstract] [Full Text]  
• Grossman, R. F. (2009). Community-Acquired Pneumonia: Advances in Management. ACCP Pulmonary Med Brd Rev 25: 359-368 [Full Text]  
• Wargo, K. A., Wright, B. M., Gupta, R. (2008). The Utility of Fluoroquinolones in the Critically Ill. Journal of Pharmacy Practice 21: 346-355 [Abstract]  
• Balsalobre, L., de la Campa, A. G. (2008). Fitness of Streptococcus pneumoniae Fluoroquinolone-Resistant Strains with Topoisomerase IV Recombinant Genes. Antimicrob. Agents Chemother. 52: 822-830 [Abstract] [Full Text]  
• Melano, R. G., Higgins, R., Seah, C., Drews, S. J., Hirakata, Y., Yamamoto, K. (2008). Evaluation of Melting Curve Analysis for Screening the Most Prevalent Mutations in Topoisomerase Genes from Streptococcus pneumoniae. J. Clin. Microbiol. 46: 396-397 [Full Text]  
• Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
• Louie, A., Brown, D. L., Liu, W., Kulawy, R. W., Deziel, M. R., Drusano, G. L. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3988-4000 [Abstract] [Full Text]  
• Olofsson, S. K., Marcusson, L. L., Stromback, A., Hughes, D., Cars, O. (2007). Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 60: 795-801 [Abstract] [Full Text]  
• Jeurissen, A., Moens, L., Raes, M., Wuyts, G., Willebrords, L., Sauer, K., Proesmans, M., Ceuppens, J. L., De Boeck, K., Bossuyt, X. (2007). Laboratory Diagnosis of Specific Antibody Deficiency to Pneumococcal Capsular Polysaccharide Antigens. Clin. Chem. 53: 505-510 [Abstract] [Full Text]  
• Fukushima, K. Y., Hirakata, Y., Sugahara, K., Yanagihara, K., Kondo, A., Kohno, S., Kamihira, S. (2006). Rapid Screening of Topoisomerase Gene Mutations by a Novel Melting Curve Analysis Method for Early Warning of Fluoroquinolone-Resistant Streptococcus pneumoniae Emergence. J. Clin. Microbiol. 44: 4553-4558 [Abstract] [Full Text]  
• Joska, T. M., Anderson, A. C. (2006). Structure-Activity Relationships of Bacillus cereus and Bacillus anthracis Dihydrofolate Reductase: toward the Identification of New Potent Drug Leads.. Antimicrob. Agents Chemother. 50: 3435-3443 [Abstract] [Full Text]  
• DeRyke, C. A., Du, X., Nicolau, D. P. (2006). Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother 58: 601-609 [Abstract] [Full Text]  
• Alou, L., Gimenez, M.-J., Sevillano, D., Aguilar, L., Cafini, F., Echeverria, O., Perez-Trallero, E., Prieto, J. (2006). A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 58: 349-358 [Abstract] [Full Text]  
• Adam, H. J., Schurek, K. N., DeCorby, M. R., Weshnoweski, B., Vashisht, R., Karlowsky, K., Hoban, D. J., Zhanel, G. G. (2006). Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates. J Antimicrob Chemother 58: 202-204 [Abstract] [Full Text]  
• Olofsson, S. K., Marcusson, L. L., Komp Lindgren, P., Hughes, D., Cars, O. (2006). Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57: 1116-1121 [Abstract] [Full Text]  
• Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
• Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., Verheij, T. J. M. (2005). Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180 [Abstract] [Full Text]  
• Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  
• Schurek, K. N., Adam, H. J., Siemens, C. G., Hoban, C. J., Hoban, D. J., Zhanel, G. G. (2005). Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J Antimicrob Chemother 56: 769-772 [Abstract] [Full Text]  
• Cottagnoud, P., Johnson, M., Cottagnoud, M., Piddock, L. (2005). Preincubation of Pneumococci with {beta}-Lactams Alone or Combined with Levofloxacin Prevents Quinolone-Induced Resistance without Increasing Intracellular Levels of Levofloxacin. Antimicrob. Agents Chemother. 49: 3517-3519 [Abstract] [Full Text]  
• Weiss, K., Tillotson, G. S. (2005). The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia. Chest 128: 940-946 [Abstract] [Full Text]  
• Reinert, R. R., Reinert, S., van der Linden, M., Cil, M. Y., Al-Lahham, A., Appelbaum, P. (2005). Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003. Antimicrob. Agents Chemother. 49: 2903-2913 [Abstract] [Full Text]  
• Ramsdell, J., Narsavage, G. L., Fink, J. B., for the American College of Chest Physicians' Home, (2005). Management of Community-Acquired Pneumonia in the Home: An American College of Chest Physicians Clinical Position Statement. Chest 127: 1752-1763 [Abstract] [Full Text]  
• Berry, V., Hoover, J., Singley, C., Woodnutt, G. (2005). Comparative Bacteriological Efficacy of Pharmacokinetically Enhanced Amoxicillin-Clavulanate against Streptococcus pneumoniae with Elevated Amoxicillin MICs and Haemophilus influenzae. Antimicrob. Agents Chemother. 49: 908-915 [Abstract] [Full Text]  
• Carratala, J., Fernandez-Sabe, N., Ortega, L., Castellsague, X., Roson, B., Dorca, J., Fernandez-Aguera, A., Verdaguer, R., Martinez, J., Manresa, F., Gudiol, F. (2005). Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia: A Randomized Trial in Low-Risk Patients. ANN INTERN MED 142: 165-172 [Abstract] [Full Text]  
• Pelton, S. I., Hammerschlag, M. R. (2005). Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children. CLIN PEDIATR 44: 1-17  
• Cottagnoud, P., Pfister, M., Acosta, F., Cottagnoud, M., Flatz, L., Kuhn, F., Muller, H.-P., Stucki, A. (2004). Daptomycin Is Highly Efficacious against Penicillin-Resistant and Penicillin- and Quinolone-Resistant Pneumococci in Experimental Meningitis. Antimicrob. Agents Chemother. 48: 3928-3933 [Abstract] [Full Text]  
• Smith, H. J., Walters, M., Hisanaga, T., Zhanel, G. G., Hoban, D. J. (2004). Mutant Prevention Concentrations for Single-Step Fluoroquinolone-Resistant Mutants of Wild-Type, Efflux-Positive, or ParC or GyrA Mutation-Containing Streptococcus pneumoniae Isolates. Antimicrob. Agents Chemother. 48: 3954-3958 [Abstract] [Full Text]  
• Higgins, P. G., Wisplinghoff, H., Stefanik, D., Seifert, H. (2004). Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 54: 821-823 [Abstract] [Full Text]  
• Powis, J., McGeer, A., Green, K., Vanderkooi, O., Weiss, K., Zhanel, G., Mazzulli, T., Kuhn, M., Church, D., Davidson, R., Forward, K., Hoban, D., Simor, A., Low, D. E. (2004). In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002. Antimicrob. Agents Chemother. 48: 3305-3311 [Abstract] [Full Text]  
• Pletz, M. W. R., McGee, L., Jorgensen, J., Beall, B., Facklam, R. R., Whitney, C. G., Klugman, K. P. (2004). Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine. Antimicrob. Agents Chemother. 48: 3491-3497 [Abstract] [Full Text]  
• Smith, H. J., Noreddin, A. M., Siemens, C. G., Schurek, K. N., Greisman, J., Hoban, C. J., Hoban, D. J., Zhanel, G. G. (2004). Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics. Antimicrob. Agents Chemother. 48: 3630-3635 [Abstract] [Full Text]  
• Song, J.-H., Jung, S.-I., Ko, K. S., Kim, N. Y., Son, J. S., Chang, H.-H., Ki, H. K., Oh, W. S., Suh, J. Y., Peck, K. R., Lee, N. Y., Yang, Y., Lu, Q., Chongthaleong, A., Chiu, C.-H., Lalitha, M. K., Perera, J., Yee, T. T., Kumarasinghe, G., Jamal, F., Kamarulzaman, A., Parasakthi, N., Van, P. H., Carlos, C., So, T., Ng, T. K., Shibl, A. (2004). High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). Antimicrob. Agents Chemother. 48: 2101-2107 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
• Harnett, S. J., Fraise, A. P., Andrews, J. M., Jevons, G., Brenwald, N. P., Wise, R. (2004). Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrob Chemother 53: 783-792 [Abstract] [Full Text]  
• File, T. M. Jr, Garau, J., Blasi, F., Chidiac, C., Klugman, K., Lode, H., Lonks, J. R., Mandell, L., Ramirez, J., Yu, V. (2004). Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest 125: 1888-1901 [Abstract] [Full Text]  
• Florea, N. R., Tessier, P. R., Zhang, C., Nightingale, C. H., Nicolau, D. P. (2004). Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 1215-1221 [Abstract] [Full Text]  
• Roson, B., Carratala, J., Fernandez-Sabe, N., Tubau, F., Manresa, F., Gudiol, F. (2004). Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia. Arch Intern Med 164: 502-508 [Abstract] [Full Text]  
• Perez-Vazquez, M., Roman, F., Aracil, B., Canton, R., Campos, J. (2004). Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations. J. Clin. Microbiol. 42: 1185-1191 [Abstract] [Full Text]  
• Low, D. E., Pichichero, M. E., Schaad, U. B. (2004). Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance. CLIN PEDIATR 43: 135-151 [Abstract]  
• Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G. (2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607 [Abstract] [Full Text]  
• Flatz, L., Cottagnoud, M., Kuhn, F., Entenza, J., Stucki, A., Cottagnoud, P. (2004). Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 53: 305-310 [Abstract] [Full Text]  
• Morrissey, I., Tillotson, G. (2004). Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 53: 144-148 [Abstract] [Full Text]  
• Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (2004). Efficacy of Garenoxacin in Treatment of Experimental Endocarditis Due to Staphylococcus aureus or Viridans Group Streptococci. Antimicrob. Agents Chemother. 48: 86-92 [Abstract] [Full Text]  
• Gunderson, S. M., Hayes, R. A., Quinn, J. P., Danziger, L. H. (2004). In Vitro Pharmacodynamic Activities of ABT-492, a Novel Quinolone, Compared to Those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 48: 203-208 [Abstract] [Full Text]  
• Canton, R., Morosini, M., Enright, M. C., Morrissey, I. (2003). Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52: 944-952 [Abstract] [Full Text]  
• Yamazaki, K., Ogura, S., Ishizaka, A., Oh-hara, T., Nishimura, M. (2003). Bronchoscopic Microsampling Method for Measuring Drug Concentration in Epithelial Lining Fluid. Am. J. Respir. Crit. Care Med. 168: 1304-1307 [Abstract] [Full Text]  
• Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E. (2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother. 47: 3542-3547 [Abstract] [Full Text]  
• Smith, C. (2003). Pharmacokinetic/Pharmacodynamic Considerations in Community-Acquired Lower Respiratory Tract Infections. Journal of Pharmacy Practice 16: 313-323 [Abstract]  
• Oosterheert, J. J., Bonten, M. J. M., Hak, E., Schneider, M. M. E., Hoepelman, I. M. (2003). How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 52: 555-563 [Abstract] [Full Text]  
• Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. The Annals of Pharmacotherapy 37: 1478-1488 [Abstract] [Full Text]  
• Restrepo, M. I., Velez, J. A., McElmeel, M. L., Whitney, C. G., Jorgensen, J. H. (2003). Activity of Daptomycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2974-2977 [Abstract] [Full Text]  
• Gold, L., Igra, H. (2003). Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature. J Am Board Fam Med 16: 458-460 [Full Text]  
• Piddock, L. J. V., Johnson, M. M., Webber, M. A. (2003). Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria. J Antimicrob Chemother 52: 500-502 [Abstract] [Full Text]  
• Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
• Kuhn, F., Cottagnoud, M., Acosta, F., Flatz, L., Entenza, J., Cottagnoud, P. (2003). Cefotaxime Acts Synergistically with Levofloxacin in Experimental Meningitis Due to Penicillin-Resistant Pneumococci and Prevents Selection of Levofloxacin-Resistant Mutants In Vitro. Antimicrob. Agents Chemother. 47: 2487-2491 [Abstract] [Full Text]  
• Morosini, M.-I., Loza, E., del Campo, R., Almaraz, F., Baquero, F., Canton, R. (2003). Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases. Antimicrob. Agents Chemother. 47: 2692-2695 [Abstract] [Full Text]  
• Dean, N. C. (2003). Encouraging News From the Antibiotic Resistance Front. Chest 124: 423-424 [Full Text]  
• Waterer, G. W., Buckingham, S. C., Kessler, L. A., Quasney, M. W., Wunderink, R. G. (2003). Decreasing {beta}-Lactam Resistance in Pneumococci From the Memphis Region: Analysis of 2,152 Isolates From 1996 to 2001. Chest 124: 519-525 [Abstract] [Full Text]  
• Jacobs, M. R., Felmingham, D., Appelbaum, P. C., Gruneberg, R. N., the Alexander Project Group, (2003). The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52: 229-246 [Abstract] [Full Text]  
• Smith, H. J., Nichol, K. A., Hoban, D. J., Zhanel, G. G. (2003). Reply. J Antimicrob Chemother 52: 313-314 [Full Text]  
• Balsalobre, L., Ferrandiz, M. J., Linares, J., Tubau, F., de la Campa, A. G. (2003). Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2072-2081 [Abstract] [Full Text]  
• Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
• Johnson, C. N., Benjamin, W. H. Jr., Moser, S. A., Hollingshead, S. K., Zheng, X., Crain, M. J., Nahm, M. H., Waites, K. B. (2003). Genetic Relatedness of Levofloxacin-Nonsusceptible Streptococcus pneumoniae Isolates from North America. J. Clin. Microbiol. 41: 2458-2464 [Abstract] [Full Text]  
• Brown, R. B., Iannini, P., Gross, P., Kunkel, M. (2003). Impact of Initial Antibiotic Choice on Clinical Outcomes in Community-Acquired Pneumonia: Analysis of a Hospital Claims-Made Database. Chest 123: 1503-1511 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Chavanet, P. (2003). Reply. J Antimicrob Chemother 51: 1308-1309 [Full Text]  
• de la Campa, A. G., Ferrandiz, M.-J., Tubau, F., Pallares, R., Manresa, F., Linares, J. (2003). Genetic Characterization of Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Isolated during Ciprofloxacin Therapy from a Patient with Bronchiectasis. Antimicrob. Agents Chemother. 47: 1419-1422 [Abstract] [Full Text]  
• Fogarty, C. M., Kohno, S., Buchanan, P., Aubier, M., Baz, M. (2003). Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 51: 947-955 [Abstract] [Full Text]  
• El Kholy, A., Baseem, H., Hall, G. S., Procop, G. W., Longworth, D. L. (2003). Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. J Antimicrob Chemother 51: 625-630 [Abstract] [Full Text]  
• Smith, H. J., Nichol, K. A., Hoban, D. J., Zhanel, G. G. (2003). Reply. J Antimicrob Chemother 51: 464-465 [Full Text]  
• Rijnders, B. J. A., Finch, R., Schurmann, D., Kubin, R., Collins, O., McGivern, J., Izquierdo, J. L., Ogundare, F. W., Hoffken, G. (2003). Moxifloxacin for Community-Acquired Pneumonia. Antimicrob. Agents Chemother. 47: 444-445 [Full Text]  
• Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
• Weiss, K., Tillotson, G. S., Guthrie, R. (2002). Fluoroquinolones for Respiratory Infection : Too Valuable To Overuse (and Too Valuable To Misuse!). Chest 122: 1102-1103 [Full Text]  
• Pericone, C. D., Bae, D., Shchepetov, M., McCool, T., Weiser, J. N. (2002). Short-Sequence Tandem and Nontandem DNA Repeats and Endogenous Hydrogen Peroxide Production Contribute to Genetic Instability of Streptococcus pneumoniae. J. Bacteriol. 184: 4392-4399 [Abstract] [Full Text]  
• Ross, J. J., Worthington, M. G., Gorbach, S. L., Tillotson, G. S., Zhao, X., Drlica, K., Zhanel, G. G., Hoban, D. J., Chan, C. K., Hutchinson, J., Low, D. E., de Azavedo, J., Bast, D. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 347: 65-67 [Full Text]  
• Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
• (2002). Fluoroquinolone-Resistant Streptococcus pneumoniae Cause Pneumococcal Pneumonia Treatment Failures. JWatch Infect. Diseases 2002: 2-2 [Full Text]